MBX Biosciences, Inc. (MBX): director Peter Radovich elected to the board

Events in this filing

Item 5.02 as filed

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of October 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Peter Radovich as a director of the Company. The Board determined that Mr. Radovich is independent under the applicable listing standards of The Nasdaq Stock Market (“Nasdaq”).
Mr. Radovich has been designated as a Class I director to serve until the Company’s 2028 Annual Meeting of Stockholders, in accordance with the Company’s amended and restated by-laws and to serve thereafter until his successor has been duly elected and qualified or until his earlier death, removal or resignation. In connection with the appointment, the Board set the size of the Board at eight directors.
In connection with his appointment as a non-employee director, Mr. Radovich will receive compensation, including an initial award of a non-qualified stock option to purchase 18,200 shares of the Company’s common stock, to be granted on the appointment date of October 20, 2026. In addition, Mr. Radovich will receive cash compensation for his Board service, in accordance with the Company’s Non-Employee Director Compensation Policy (as amended March 2026), which was previously described in the Company’s Annual Proxy Statement for the period ending December 31, 2025, filed with the Securities and Exchange Commission on April 22, 2026. In addition, in connection with his election, the Company is entering into an indemnification agreement with Mr. Radovich in the same form as used with the Company’s other directors.
There are no arrangements or understandings between Mr. Radovich and any other persons pursuant to which he was selected as a director of the Company, and there are no transactions in which Mr. Radovich has an interest requiring disclosure under Item 404(a) of Regulation S-K.